Atrys Health (ATRY) Q3 2024 earnings summary

Executive summary

• Achieved Adjusted EBITDA of €31.2M in the first nine months of 2024, up 31.7% year-over-year.

• Revenues reached €155.6M, reflecting 7.2% growth at constant exchange rates.

• Strongest growth observed in LATAM, with revenues up 10.6% (18.6% at constant exchange rates).

Financial highlights

• Gross margin increased 4.2% year-over-year to €102.6M, with a margin of 66%.

• EBITDA rose 33.1% to €26.2M; Adjusted EBITDA margin improved from 16.09% to 20.02%.

• Operating cash flow surged 60.8% to €18.3M by September 2024.

• CAPEX investment contained at €7.97M, down 4.6%.

Segment performance

• Diagnostics revenues grew 5% to €48.6M (9.5% at constant exchange rates); laboratories segment up 30.9%.

• Oncology segment revenues increased 7.6% to €45.6M; Medical Oncology up 11.6%, driven by Mexico.

• Prevention area turnover rose 5.1% to €61.4M, supported by a 4% rise in check-ups and 2% higher average ticket.